

Kevin D Read

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6480158/publications.pdf>

Version: 2024-02-01

70
papers

3,870
citations

147566

31
h-index

128067

60
g-index

74
all docs

74
docs citations

74
times ranked

5203
citing authors

#	ARTICLE	IF	CITATIONS
1	Compounds enhancing human sperm motility identified using a high-throughput phenotypic screening platform. <i>Human Reproduction</i> , 2022, 37, 466-475.	0.4	6
2	Repositioning of a Diaminotiazole Series Confirmed to Target the Cyclin-Dependent Kinase CRK12 for Use in the Treatment of African Animal Trypanosomiasis. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5606-5624.	2.9	8
3	Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 409-423.	2.9	15
4	A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market. <i>Molecules</i> , 2021, 26, 1396.	1.7	15
5	Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5905-5930.	2.9	25
6	Preparation, biological & cheminformatics-based assessment of N2,N4-diphenylpyrimidine-2,4-diamine as potential Kinase-targeted antimalarials. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 46, 116348.	1.4	5
7	Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of <i>Mycobacterium tuberculosis</i> Growth. <i>ACS Omega</i> , 2021, 6, 2284-2311.	1.6	19
8	Setting Our Sights on Infectious Diseases. <i>ACS Infectious Diseases</i> , 2020, 6, 3-13.	1.8	17
9	Targeting N-myristoylation for therapy of B-cell lymphomas. <i>Nature Communications</i> , 2020, 11, 5348.	5.8	35
10	Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy. <i>European Journal of Medicinal Chemistry</i> , 2020, 207, 112849.	2.6	13
11	Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9523-9539.	2.9	8
12	Identification of 6-amino-1 <i>H</i> -pyrazolo[3,4- <i>d</i>]pyrimidines with <i>in vivo</i> efficacy against visceral leishmaniasis. <i>RSC Medicinal Chemistry</i> , 2020, 11, 1168-1177.	1.7	2
13	Discovery and Optimization of a Compound Series Active against <i>Trypanosoma cruzi</i> , the Causative Agent of Chagas Disease. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3066-3089.	2.9	8
14	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. <i>PLoS Pathogens</i> , 2020, 16, e1008932.	2.1	16
15	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. , 2020, 16, e1008932.		0
16	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. , 2020, 16, e1008932.		0
17	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. , 2020, 16, e1008932.		0
18	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. , 2020, 16, e1008932.		0

#	ARTICLE	IF	CITATIONS
19	A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites. <i>Communications Biology</i> , 2019, 2, 271.	2.0	36
20	Substituted Aminoacetamides as Novel Leads for Malaria Treatment. <i>ChemMedChem</i> , 2019, 14, 1329-1335.	1.6	5
21	Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 7015-7020.	3.3	94
22	Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9318-9323.	3.3	119
23	Discovery of Soft-Drug Topical Tool Modulators of Sphingosine-1-phosphate Receptor 1 (S1PR1). <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 341-347.	1.3	5
24	Loss of CRMP2 O-GlcNAcylation leads to reduced novel object recognition performance in mice. <i>Open Biology</i> , 2019, 9, 190192.	1.5	17
25	Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1180-1202.	2.9	33
26	Pharmacological Validation of <i>N</i> -Myristoyltransferase as a Drug Target in <i>Leishmania donovani</i> . <i>ACS Infectious Diseases</i> , 2019, 5, 111-122.	1.8	55
27	Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies. <i>Blood</i> , 2019, 134, 3362-3362.	0.6	4
28	2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and <i>Mycobacterium tuberculosis</i> : Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization. <i>ACS Infectious Diseases</i> , 2018, 4, 954-969.	1.8	49
29	Chemical synthesis, characterisation and in vitro and in vivo metabolism of the synthetic opioid MT-45 and its newly identified fluorinated analogue 2F-MT-45 with metabolite confirmation in urine samples from known drug users. <i>Forensic Toxicology</i> , 2018, 36, 359-374.	1.4	26
30	Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2 <i>S</i> ,4 <i>R</i>)-1-((<i>S</i>)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy- <i>N</i> -(4-(4-methylthiazol-2-yl)phenyl)thiazole (VH298). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 599-618.	2.9	106
31	A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant <i>N</i> -Myristoyltransferase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8374-8389.	2.9	41
32	Identification of Morpholino Thiophenes as Novel <i>Mycobacterium tuberculosis</i> Inhibitors, Targeting QcrB. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6592-6608.	2.9	43
33	2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagas™ disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 3025-3030.	1.0	5
34	Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. <i>Nature</i> , 2018, 560, 192-197.	18.7	112
35	Discovery of super soft-drug modulators of sphingosine-1-phosphate receptor 1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 3255-3259.	1.0	18
36	Pharmacokinetics of β -Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future. <i>ACS Infectious Diseases</i> , 2018, 4, 1439-1447.	1.8	26

#	ARTICLE	IF	CITATIONS
37	Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles. <i>PLoS Pathogens</i> , 2018, 14, e1006850.	2.1	26
38	Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. <i>Nature Reviews Microbiology</i> , 2017, 15, 217-231.	13.6	315
39	Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in <i>Leishmania donovani</i> . <i>ACS Infectious Diseases</i> , 2017, 3, 718-727.	1.8	22
40	Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against <i>Trypanosoma cruzi</i> . <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7284-7299.	2.9	31
41	Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9790-9806.	2.9	14
42	Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the <i>Plasmodium falciparum</i> Drug Target, Prolyl-tRNA-synthetase. <i>ACS Infectious Diseases</i> , 2017, 3, 34-44.	1.8	45
43	Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against <i>Mycobacterium tuberculosis</i> . <i>ACS Infectious Diseases</i> , 2017, 3, 18-33.	1.8	77
44	Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in <i>Leishmania</i> . <i>PLoS Pathogens</i> , 2016, 12, e1005971.	2.1	73
45	Metabolomics and lipidomics reveal perturbation of sphingolipid metabolism by a novel anti-trypanosomal 3-(oxazolo[4,5-b]pyridine-2-yl)anilide. <i>Metabolomics</i> , 2016, 12, 1.	1.4	28
46	Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9672-9685.	2.9	66
47	Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9686-9720.	2.9	30
48	Nitroheterocyclic drugs cure experimental <i>Trypanosoma cruzi</i> infections more effectively in the chronic stage than in the acute stage. <i>Scientific Reports</i> , 2016, 6, 35351.	1.6	72
49	Potent and selective chemical probe of hypoxic signalling downstream of HIF-1 α hydroxylation via VHL inhibition. <i>Nature Communications</i> , 2016, 7, 13312.	5.8	167
50	Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6101-6120.	2.9	13
51	The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. <i>ELife</i> , 2016, 5, .	2.8	67
52	Discovery of Inhibitors of <i>Trypanosoma brucei</i> by Phenotypic Screening of a Focused Protein Kinase Library. <i>ChemMedChem</i> , 2015, 10, 1809-1820.	1.6	15
53	Development of Small Molecule <i>Trypanosoma brucei</i> N-Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode. <i>ChemMedChem</i> , 2015, 10, 1821-1836.	1.6	20
54	Development of a Fluorescence-based <i>Trypanosoma cruzi</i> CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004014.	1.3	43

#	ARTICLE	IF	CITATIONS
55	A novel multiple-stage antimalarial agent that inhibits protein synthesis. <i>Nature</i> , 2015, 522, 315-320.	13.7	353
56	Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of <i>Trypanosoma brucei</i> . <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7695-7706.	2.9	28
57	Lead Optimization of a Pyrazole Sulfonamide Series of <i>Trypanosoma brucei</i> <i>N</i> -Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9855-9869.	2.9	57
58	Discovery of β 2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1005-1010.	1.3	65
59	The <i>R</i> Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4699-4706.	1.4	62
60	The Anti-Trypanosome Drug Fexinidazole Shows Potential for Treating Visceral Leishmaniasis. <i>Science Translational Medicine</i> , 2012, 4, 119re1.	5.8	126
61	Combining PET Biodistribution and Equilibrium Dialysis Assays to Assess the Free Brain Concentration and BBB Transport of CNS Drugs. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 874-883.	2.4	53
62	Discovery of a Novel Class of Orally Active Trypanocidal <i>N</i> -Myristoyltransferase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 140-152.	2.9	102
63	Target Validation: Linking Target and Chemical Properties to Desired Product Profile. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1275-1283.	1.0	99
64	Optimisation of the Anti- <i>Trypanosoma brucei</i> Activity of the Opioid Agonist U50488. <i>ChemMedChem</i> , 2011, 6, 1832-1840.	1.6	7
65	Identification of a β -opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. <i>Biochemical Pharmacology</i> , 2010, 80, 1478-1486.	2.0	69
66	<i>N</i> -myristoyltransferase inhibitors as new leads to treat sleeping sickness. <i>Nature</i> , 2010, 464, 728-732.	13.7	272
67	Assessing brain free fraction in early drug discovery. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 337-344.	1.5	65
68	Receptor Occupancy and Brain Free Fraction. <i>Drug Metabolism and Disposition</i> , 2009, 37, 753-760.	1.7	114
69	The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. <i>Epilepsy Research</i> , 2009, 85, 96-106.	0.8	41
70	Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 205-213.	1.3	247